Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting-Reference-Cited by-同舟云学术

Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting

Published:2015-12 Issue:12 Volume:46 Page:1842-1849
ISSN:0046-8177
Container-title:Human Pathology
language:en
Short-container-title:Human Pathology

Author:

Green Ian F.,Zynger Debra L.

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference26 articles.

1. The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma;Hicks;Biotech Histochem,2013

2. Image analysis of HER2 immunohistochemical staining reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique;Minot;Am J Clin Pathol,2012

3. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy;Ross;Oncologist,2003

4. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues;Owens;Clin Breast Cancer,2004

5. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma;Hoang;Am J Clin Pathol,2000

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complementary Tumor Diagnosis by Single Cell–Based Cytogenetics Using Multi‐marker Fluorescence In Situ Hybridization (mFISH);Current Protocols;2023-11

2. HER2 Testing in the Era of Changing Guidelines;Her2-Positive Breast Cancer;2019

3. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification;Journal of Experimental & Clinical Cancer Research;2017-10-13

4. Improving accuracy of breast cancer biomarker testing in India;INDIAN J MED RES;2017

5. Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study;Virchows Archiv;2016-05-25